We wish to draw attention to the possibility of repurposing the existing calcium channel blocking drug tetrandrine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Tetrandrine is a bisbenzylisoquinoline that can be extracted from the perennial vine plant Stephania tetrandra S Moore (Chinese patent WO2004009106A1, 2002), which has been used in traditional Chinese medicine (TCM) (1-3, and references therein). It can also be synthesized chemically (US Patent 10,023,584 B2, 2018 4). There is extensive literature on the potential anti-inflammatory, immunosuppressive, oncological, and cardiovascular effects of tetrandrine. 2,5-7 It is licensed in China for the treatment of silicosis, but to our knowledge has not been licensed for viral illnesses in any country to date.